Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4
Index Copernicus  – 168.52; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 415–416

doi: 10.17219/acem/104539

Publication type: letter to editor

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Response to the article “Perioperative standards for the treatment of coagulation disorders and usage of blood products in patients undergoing liver transplantation used in the Clinic for Transplant Surgery in Wrocław”

Jan Pluta1,D,E,F, Agnieszka Cieniewicz1,D,F, Janusz Trzebicki1,D,E,F

1 Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Poland


We read with interest the article by Łukaszewski et al. published in Advances in Clinical and Experimental Medicine:1211–1215, published online on July 18th, 2018, as ahead of print). As enthusiasts of promoting global assays of hemostasis, we would like to commend the authors for their commitment and effort in their implementation and clinical application. As the authors rightly pointed out in the article, perioperative care of liver transplantation (OLTx) patients is challenging for transplant team members due to the risk of severe changes in global hemostasis. Łukaszewski et al. presented a single center experience in using rotational thromboelastometry (ROTEM) to monitor hemostasis during liver transplantation. In our center, this method has been used routinely since 2008. So far it has been used in over 400 patients undergoing OLTx. Considering the potential contribution to thrombotic complications (including portal vein thrombosis after liver transplantation), we believe that antifibrinolytic treatment should be reserved for patients with active bleeding and hyperfibrinolysis confirmed by ROTEM. The available literature indicates an increased risk of thrombotic complications in patients receiving antifibrinolytic therapy. This raises an important question for the authors about the reason for using Exacyl® in all 12 of the cases presented, even in patients who did not require any blood product transfusion. We hope that our letter will open up further discussion on this subject, which is undoubtedly crucial for OLTx patients’ safety.

Key words

hemostasis, liver transplantation, thromboelastometry, hyperfibrinolysis, tranexamic acid

References (6)

  1. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: Evidence and clinical consequences. Blood. 2010;116(6):878–885.
  2. Trzebicki J, Flakiewicz E, Kosieradzki M, et al. The use of thromboelastometry in the assessment of hemostasis during orthotopic liver transplantation reduces the demand for blood products. Ann Transplant. 2010;15(3):19–24.
  3. Abuelkasem E, Lu S, Tanaka K, Planinsic R, Sakai T. Comparison between thrombelastography and thromboelastometry in hyperfibrinolysis detection during adult liver transplantation. Br J Anaesth. 2016;116(4):507–512.
  4. Görlinger K. Coagulation management during liver transplantation [in German]. Hamostaseologie. 2006;26(3 Suppl 1):S64–S75.
  5. Lier H, Vorweg M, Hanke A, Görlinger K. Thromboelastometry guided therapy of severe bleeding. Essener Runde algorithm. Hamostaseologie. 2013;33(1):51–61.
  6. Ortmann E, Besser MW, Klein AA. Antifibrinolytic agents in current anaesthetic practice. Br J Anaesth. 2013;111(4):549–563.